CANCER BIOLOGY AND SIGNALING ABSTRACT The overarching goal of the Cancer Biology and Signaling Program (CBS) is to provide fundamental scientific knowledge for the molecular and cellular basis of cancer (including initiation, progression, and metastasis) and the interaction between cancer and the immune system. Scientific discoveries of CBS members are aimed to provide molecular targets for cancer detection, diagnosis, and therapy through 2 aims: 1) understand signaling pathways involved in cell growth regulation; 2) investigate the molecular mechanisms of oncogenic development and progression. For these goals, research conducted by CBS members during the current project period has made a number of major advancements on signaling pathways in cell growth control, mechanisms of oncogenes and tumor suppressors in oncogenesis, and interaction between cancer and host immune system. The central themes of CBS include 1) signal transduction and 2) cell growth, with a developing focus on immunity in tumorigenesis. Drs. Dong-Er Zhang and Kun-Liang Guan have been CBS co-leaders since 2008. They have complementary expertise (alteration of transcription of liquid cancer development and signal transduction regulating growth of solid cancer cells) and share a common vision for future success of CBS, which will continue to advance basic knowledge and provide the scientific basis for early cancer prevention, detection, and treatment. The 52 members of CBS represent 11 departments and 3 schools. In 2017, CBS members had $18.6M in cancer-relevant, peer-reviewed funding (direct costs), of which $8.3M (45%) was from NCI, $9.1M (49%) was from other NIH sources, and $1.1M (6%) was from other peer-reviewed agencies. In addition, CBS members had $1.6M in cancer-relevant, non-peer reviewed funding (direct costs) During the project period (2013-2017), members authored 669 cancer-relevant publications, of which 78 (12%) were intra-programmatic, 162 (24%) were inter-programmatic, and 190 (28%) were collaborative with investigators from other NCI- designated cancer centers.
| Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135 |
| Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42 |
| Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593 |
| Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69 |
| Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089 |
| Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809 |
| Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev : |
| Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36 |
| Ramdani, Ghania; Schall, Nadine; Kalyanaraman, Hema et al. (2018) cGMP-dependent protein kinase-2 regulates bone mass and prevents diabetic bone loss. J Endocrinol 238:203-219 |
| Nguyen, Vi; Marmor, Rebecca A; Ramamoorthy, Sonia L et al. (2018) The Use of Solicited Publishing by Academic Surgeons. Surgery 164:212-218 |
Showing the most recent 10 out of 862 publications
